Overview

Our
Company

NorthStar is a radiopharmaceutical company, developing novel ways to help detect and cure cancer and other serious diseases. We are the first and only U.S. company housing commercial scale radioisotope production and radiopharmaceutical CDMO services co-located on the same campus.

 

We are routinely producing Copper-67 (Cu-67), used in clinical trials for the treatment of several types of cancer.

IN OUR EFFORTS TO DELIVER
CREATIVE SOLUTIONS, WE
CLEARLY DEFINE

WHO
WE ARE

We are innovators who revolutionized the U.S. production of Mo-99, and now Cu-67. Actinium-225 (Ac-225) will begin production soon. We are dedicated to preserving the environment using non-uranium production methods. We are pioneers working with industry leaders to develop and commercialize new diagnostics and radiopharmaceutical therapies that will serve the next generation of medical advances for patients.

The next major horizon includes a world class Radiopharmaceutical CDMO/CMO, launching production operations in early 2025.

THE RAPIDLY EVOLOVING
RADIOPHARMACEUTICAL MARKET
DEMANDS INNOVATIVE THINKING,
LIKE THAT PIONEERED BY OUR

LEADERSHIP
TEAM

Our executive team brings proven experience and expertise in developing and commercializing innovative nuclear medicine products and technologies.

LATEST NEWS, PRESS RELEASES & EVENTS


News - Jan 22, 2024
NorthStar Medical Radioisotopes: Enabling Radiopharmaceutical Company Success

Press Releases - Jan 8, 2024
NorthStar Medical Radioisotopes and Alpha-9 Oncology Enter Strategic Long-term Agreement for Supply of Actinium-225 (Ac-225)

Press Releases - Jan 3, 2024
NorthStar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration Agreement for Development and Production of Actinium-225 (Ac-225)-based Therapeutic Radiopharmaceuticals for Treatment of Primary and Metastatic Solid Tumors
Feb 22, 2024 - Feb 23, 2024
Workshop
International Workshop on Standards and Measurements for Alpha Emitting Nuclides in Therapeutic Nuclear Medicine
Attending, Speaking